MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
Thanks to the lovely algorithms social media is using, we may only reach some of you with some posts, so here are a few of our latest articles and podcasts. We always encourage you to
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
UCSF Neurosurgeon Dr. Manish Aghi, MD, Ph.D. Professor of Neurological Surgery UCSF Weill Institute for Neurosciences presents “Endoscopic surgery for sellar and parasellar tumors – Lessons learned in the OR and laboratory.”
San Diego, California-based Crinetics Pharmaceutical announced today that its novel investigational drug paltusotine maintained IGf-1 levels in patients who switched from monthly injectables
In a recent JAMA Network article covering the COVID-19 pandemic, 23.3% of physicians reported personal attacks on social media. Online bullying and social media harassment are nothing new, but this behavior, plus considerable misinformation, makes disseminating helpful, accurate content an ongoing challenge.
On February 28, many organizations that advocate for cures, therapies, drugs, and critically early diagnosis for the known 7000 plus rare diseases join forces to focus on rare diseases. We support rarediseaseday.org and the many
From Jorge D. Faccinetti – co-founder. With a pituitary disease like acromegaly, Cushing’s, hypopituitarism, and others, or for that matter, any other chronic condition, a big part of the battle is to get up every
A presentation from Lewis Blevins, M.D. Pituitary World News cofounder and Medical Director of the California Center for Pituitary Disorders at UCSF on the emerging clinical insights of hypercortisolism. Click here to view the presentation.
Not surprisingly, COVID-19 appears to have significantly impacted pituitary patients’ access to healthcare. Our brief survey elicited information from respondents on their experiences and attitudes towards obtaining healthcare via telemedicine. Dr. Blevins shares the findings
Joining a new drug trial, for example, is an action that can benefit many affected with a disease, particularly with a rare disease, where finding enough people for an adequate sample is very challenging.
If you’d like to learn more about Addison’s disease, here’s a perfect opportunity to do so. The Advanced Practice in Endocrinology Nursing is a comprehensive resource on Adrenal Insufficiency and three chapters from the book are
From J D Faccinetti – co-founder – One of the unforeseen consequences of this crisis is how it has affected our editorial decisions, that is, deciding what to write and when to publish. The media